7th Jul 2014 08:10
LONDON (Alliance News) - Summit Corp PLC said Monday it has seen encouraging results from its Phase 1b trial of its duchenne muscular dystrophy treatment SMT C1100.
Duchenne muscular dystrophy is a genetic condition that causes muscle weakness.
The treatment showed a statistically significant decrease in key enzymes associated with muscle damage in the blood, it said. Patients with the disease have weaker muscle cells due to a lack of dystrophin, which causes enzymes including creatine kinase, aspartate aminotransferase and alanin aminotransferase to leak out into the blood.
The results provided further encouragement of the potential of its treatment for the disorder, the company said, and support further evaluation in a placebo-controlled study.
Shares in Summit were trading up 2.2% at 142.01 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
SUMM.L